News

Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a Cooperative Research and Development Agreement…
Read More...

Dova Pharmaceutical and Salix Pharmaceuticals announced that they have entered into an exclusive agreement to co-promote Dova’s DOPTELET (avatrombopag) in the United States (U.S.). The…
Read More...

Selexis SA and Hoba Therapeutics announced that they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 (rhMeteorin) for the treatment of…
Read More...

Alexion Pharmaceuticals and Syntimmune announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing…
Read More...

AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a Type-II variation update…
Read More...

Myelo Therapeutics GmbH announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the…
Read More...

Infor announced that Ibnsina Pharma has invested in Infor EAM, Infor d/EPM, Infor M3, Infor SCE (Warehouse Management System), and Infor OS to help unify and integrate its business…
Read More...

Cerecor announced that it has agreed to acquire Ichorion Therapeutics, Inc. Ichorion is a privately-held biopharmaceutical company focused on developing treatments and increasing…
Read More...

PeptiDream announced that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals. Under the agreement, PeptiDream…
Read More...

Tris Pharma announced the acquisition of NextWave Pharmaceuticals (NextWave), a wholly owned subsidiary of Pfizer Inc. (Pfizer), including two key Attention Deficit Hyperactivity…
Read More...

Sarepta Therapeutics announced that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy…
Read More...

AstraZeneca and MedImmune announced that the European Commission has granted marketing authorisation for Imfinzi (durvalumab) as monotherapy for the treatment of locally-advanced,…
Read More...

Gilead Sciences announced plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading…
Read More...

MEBIAS Discovery, an emerging leader in the field of drug discovery targeting G-protein coupled receptors, has secured grant funding from the National Institute of Drug Abuse (NIDA) to…
Read More...

Celltrion, Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. ‘Incubation’…
Read More...

AGC Biologics announced that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing…
Read More...

PharmaBlock Sciences recently announced the appointment of Dr. Shijie Zhang as Chief Technology Officer. Shijie joins the company from Agios Pharmaceuticals, Inc., where he was Director…
Read More...

Seattle Genetics announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry of Health, Labour and Welfare for…
Read More...

BIA Separations announced the expansion of its services with the opening of a new upstream processing (USP) laboratory. The investment in the new facility comes in response to…
Read More...

Neurimmune announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered into a…
Read More...